{'fraction_non_alphanumeric': 0.02112676056338028, 'fraction_numerical': 0.0, 'mean_word_length': 5.292035398230088, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The use of intravenous immune globulin in organ transplantation.

There are no comparative clinical data to differentiate the available IVIG products. Cost, pharmaceutical considerations, and CMV titers are criteria for selecting these products. CMV-IGIV has higher titers of CMV antibodies but is more costly. The potential for CMV infection in transplant patients is great, but the clinical significance may vary. Likewise CMV morbidity and mortality is variable and dependent on the type of transplant, the donor, and immunosuppressive regimens used. IVIG has a role in decreasing CMV infections in transplant patients, but further study and cost-benefit analysis is necessary to determine optimal regimens.